Related Experiment Video

Updated: May 8, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Current clinical trials with polo-like kinase 1 inhibitors in solid tumors

Hyungshin Yim1

  • 1Department of Pharmacy, College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Gyeonggi-do, Republic of Korea.

Anti-Cancer Drugs
|August 17, 2013
PubMed

Insights

Polo-like kinase 1 (PLK1) inhibitors show promise in cancer therapy, with ongoing clinical trials evaluating their safety and efficacy. Further research is needed to identify optimal patient populations and biomarkers for these targeted cancer drugs.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Targeted cancer therapies have advanced significantly due to a better understanding of malignant transformation.
  • Polo-like kinase 1 (PLK1) is a validated target for cancer therapy, with several inhibitors developed.

Purpose of the Study:

  • To analyze the clinical status of PLK1 inhibitors, including BI 2536, volasertib, and GSK461364A.
  • To evaluate the significance of PLK1 inhibitors in cancer patients.

Main Methods:

  • Review of clinical trial data for BI 2536, volasertib, and GSK461364A.
  • Analysis of preclinical and clinical study outcomes for PLK1 inhibitors.

Main Results:

  • BI 2536 monotherapy is terminated, but combination studies continue. Volasertib shows improved profiles and is in Phase I/II trials.
  • GSK461364A demonstrated enhanced antitumor effects in p53-mutated cancers but requires anticoagulation due to thrombotic risks.
  • PLK1 inhibitors generally exhibit favorable pharmacokinetics, safety, and efficacy in solid tumors.

Conclusions:

  • PLK1 inhibitors represent a promising class of targeted cancer therapies.
  • Further investigation is warranted in specific patient populations, such as those with mutated p53 or Ras and high PLK1 levels, to optimize treatment strategies and evaluation criteria.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...